"Everolimus" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A derivative of sirolimus and an inhibitor of TOR SERINE-THREONINE KINASES. It is used to prevent GRAFT REJECTION in heart and kidney transplant patients by blocking cell proliferation signals. It is also an ANTINEOPLASTIC AGENT.
| Descriptor ID |
D000068338
|
| MeSH Number(s) |
D02.540.505.760.500
|
| Concept/Terms |
Everolimus- Everolimus
- SDZ RAD
- RAD, SDZ
- SDZ-RAD
- 40-O-(2-hydroxyethyl)-rapamycin
|
Below are MeSH descriptors whose meaning is more general than "Everolimus".
Below are MeSH descriptors whose meaning is more specific than "Everolimus".
This graph shows the total number of publications written about "Everolimus" by people in this website by year, and whether "Everolimus" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2012 | 0 | 1 | 1 |
| 2016 | 3 | 1 | 4 |
| 2017 | 1 | 0 | 1 |
| 2018 | 0 | 1 | 1 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Everolimus" by people in Profiles.
-
Everolimus and Low-Dose Tacrolimus After Heart Transplant in Children: A Randomized Clinical Trial. JAMA. 2025 Oct 21; 334(15):1339-1348.
-
Increased fatty acid delivery by tumor endothelium promotes metastatic outgrowth. JCI Insight. 2025 May 08; 10(9).
-
TCA metabolism regulates DNA hypermethylation in LPS and Mycobacterium tuberculosis-induced immune tolerance. Proc Natl Acad Sci U S A. 2024 Oct 08; 121(41):e2404841121.
-
Adjuvant Everolimus in Non-Clear Cell Renal Cell Carcinoma: A Secondary Analysis of a Randomized Clinical Trial. JAMA Netw Open. 2024 08 01; 7(8):e2425288.
-
Adjuvant Everolimus in Patients with Completely Resected, Very High-risk Renal Cell Carcinoma of Clear Cell Histology: Results from the Phase 3 Placebo-controlled SWOG S0931 (EVEREST) Trial. Eur Urol. 2024 Sep; 86(3):258-264.
-
Mining the Metabolic Capacity of Clostridium sporogenes Aided by Machine Learning. Angew Chem Int Ed Engl. 2024 03 18; 63(12):e202319925.
-
To Absorb or Not to Absorb: That Is the Question! J Vasc Interv Radiol. 2023 06; 34(6):1036-1037.
-
A phase I/II study of preoperative letrozole, everolimus, and carotuximab in stage 2 and 3 hormone receptor-positive and Her2-negative breast cancer. Breast Cancer Res Treat. 2023 Apr; 198(2):217-229.
-
Safety and activity of vandetanib in combination with everolimus in patients with advanced solid tumors: a phase I study. ESMO Open. 2021 04; 6(2):100079.
-
A Phase I and Surgical Study of Ribociclib and Everolimus in Children with Recurrent or Refractory Malignant Brain Tumors: A Pediatric Brain Tumor Consortium Study. Clin Cancer Res. 2021 05 01; 27(9):2442-2451.